Cytodyn Inc (CYDY)

[stockorus]

The article cited by daemon has this in the abstract:

The incidences of key treatment-related adverse events of grade 3 or higher were neutropenia (51% with sacituzumab govitecan and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and <1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). There were three deaths owing to adverse events in each group; no deaths were considered to be related to sacituzumab govitecan treatment.

CONCLUSIONS

Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan.

Our drug is given along with Carboplatin, so the combo may have sae coming from carbo. Not sure how that would compare with SG effects stated above. Also the SG trial had control of some other chemo drugs:

"we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician’s choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-negative breast cancer. "

The article's abstract does not say the SG arm was a combination therapy with some form of chemo, or whether it was single agent SG vs single agent Chemo.